Thromboprophylaxis With Rivaroxaban In Patients With Malignancy and Central Venous Lines

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 105 participants.

Also called NCT03506815

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 105 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03506815
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03506815. Randomized; no masking; primary purpose prevention. Start 2019-03-15 (actual); primary completion 2020-05-14 (actual). Results posted on 2024-07-05.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Thromboprophylaxis With Rivaroxaban In Patients With Malignancy and Central Venous Lines
Acronym
TRIM-Line
Condition
Upper Extremity Deep Vein Thrombosis
Condition
Central Venous Catheter Thrombosis
Condition
Cancer
Intervention (Drug)
Rivaroxaban 10 MG
Lead sponsor
Ottawa Hospital Research Institute (class: other)
Collaborator
Queen Elizabeth II Health Sciences Centre (class: other)
Collaborator
University of Alberta (class: other)
Collaborator
Hamilton Health Sciences Corporation (class: other)

Record details

Record id
cardio:ct-nct03506815
Content hash
b9ee0da56bd8d0763698d55b78ff05602e729cb2a4a97fcbfa736c655985e7df